Page last updated: 2024-08-07 15:46:22
72 kDa type IV collagenase
A 72 kDa type IV collagenase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P08253]
Synonyms
EC 3.4.24.24;
72 kDa gelatinase;
Gelatinase A;
Matrix metalloproteinase-2;
MMP-2;
TBE-1
Research
Bioassay Publications (120)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (9.17) | 18.2507 |
| 2000's | 58 (48.33) | 29.6817 |
| 2010's | 43 (35.83) | 24.3611 |
| 2020's | 8 (6.67) | 2.80 |
Compounds (80)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| 2,3-dihydroxybenzoic acid | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| protocatechuic acid | Homo sapiens (human) | IC50 | 137.0000 | 1 | 1 |
| gallic acid | Homo sapiens (human) | IC50 | 65.0086 | 1 | 7 |
| beta-resorcylic acid | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| oxyquinoline | Homo sapiens (human) | IC50 | 130.0000 | 1 | 1 |
| acetohydroxamic acid | Homo sapiens (human) | IC50 | 15,000.0000 | 1 | 1 |
| 2,5-dihydroxybenzoic acid | Homo sapiens (human) | IC50 | 115.0000 | 1 | 1 |
| nafamostat | Homo sapiens (human) | IC50 | 420.0000 | 1 | 1 |
| veratric acid | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| methyl gallate | Homo sapiens (human) | IC50 | 26.5000 | 1 | 2 |
| 3,4,5-trimethoxybenzoic acid | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| syringic acid | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| tropolone | Homo sapiens (human) | IC50 | 146.0000 | 1 | 1 |
| methylene diphosphonate | Homo sapiens (human) | IC50 | 49.0000 | 1 | 1 |
| clodronic acid | Homo sapiens (human) | IC50 | 145.0000 | 1 | 1 |
| daunorubicin | Homo sapiens (human) | IC50 | 1.9000 | 1 | 1 |
| tiludronic acid | Homo sapiens (human) | IC50 | 7.2000 | 1 | 1 |
| epigallocatechin gallate | Homo sapiens (human) | IC50 | 7.6143 | 2 | 7 |
| zoledronic acid | Homo sapiens (human) | IC50 | 7.0000 | 2 | 2 |
| piloty's acid | Homo sapiens (human) | Ki | 55.5100 | 3 | 10 |
| ubenimex | Homo sapiens (human) | IC50 | 126.5247 | 17 | 17 |
| 8-mercaptoquinoline | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| marimastat | Homo sapiens (human) | IC50 | 0.7167 | 14 | 14 |
| marimastat | Homo sapiens (human) | Ki | 0.0006 | 1 | 1 |
| n-(2-isobutyl-3-(n'-hydroxycarbonylamido)propanoyl)-o-methyltyrosinemethylamide | Homo sapiens (human) | IC50 | 0.0060 | 1 | 1 |
| n-(2-isobutyl-3-(n'-hydroxycarbonylamido)propanoyl)-o-methyltyrosinemethylamide | Homo sapiens (human) | Ki | 0.0010 | 1 | 1 |
| ilomastat | Homo sapiens (human) | IC50 | 0.0031 | 13 | 13 |
| ilomastat | Homo sapiens (human) | Ki | 0.0004 | 3 | 3 |
| bb3497 | Homo sapiens (human) | IC50 | 15.0000 | 1 | 1 |
| procyanidin C1 | Homo sapiens (human) | IC50 | 31.4000 | 1 | 1 |
| 3-((benzyl)(methylaminocarbonyl)methylaminocarbonyl)n-hydroxy-5-methylhexanamide | Homo sapiens (human) | IC50 | 0.0023 | 2 | 2 |
| 2-(4-aminophenyl)benzothiazole | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| taxifolin | Homo sapiens (human) | IC50 | 22.6200 | 1 | 1 |
| actinonin | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| cgs 27023a | Homo sapiens (human) | IC50 | 0.0297 | 3 | 3 |
| cgs 27023a | Homo sapiens (human) | Ki | 0.0260 | 1 | 4 |
| aclarubicin | Homo sapiens (human) | IC50 | 9.9000 | 1 | 1 |
| prinomastat | Homo sapiens (human) | IC50 | 0.0005 | 7 | 7 |
| prinomastat | Homo sapiens (human) | Ki | 0.0001 | 4 | 4 |
| isoliquiritigenin | Homo sapiens (human) | IC50 | 0.0100 | 1 | 1 |
| caffeic acid | Homo sapiens (human) | IC50 | 0.0243 | 1 | 1 |
| 4-thiouracil | Homo sapiens (human) | IC50 | 121.0000 | 1 | 1 |
| rs-130830 | Homo sapiens (human) | IC50 | 0.0001 | 6 | 6 |
| rs-130830 | Homo sapiens (human) | Ki | 0.1027 | 3 | 8 |
| pnu 142372 | Homo sapiens (human) | Ki | 3.0000 | 1 | 1 |
| pnu 107859 | Homo sapiens (human) | Ki | 3.0000 | 1 | 1 |
| quercetin | Homo sapiens (human) | IC50 | 6.6800 | 1 | 1 |
| luteolin | Homo sapiens (human) | IC50 | 3.6100 | 1 | 1 |
| amentoflavone | Homo sapiens (human) | IC50 | 30.3100 | 1 | 1 |
| robustaflavone | Homo sapiens (human) | IC50 | 10.2200 | 1 | 1 |
| trans-2,3',4,5'-tetrahydroxystilbene | Homo sapiens (human) | IC50 | 27.6000 | 1 | 1 |
| ginkgolic acid | Homo sapiens (human) | IC50 | 6.3000 | 1 | 1 |
| tmi-1 | Homo sapiens (human) | IC50 | 0.0103 | 4 | 9 |
| bilobetin | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| batimastat | Homo sapiens (human) | IC50 | 0.3029 | 6 | 6 |
| isoacteoside | Homo sapiens (human) | IC50 | 8.9600 | 1 | 1 |
| Methyl rosmarinate | Homo sapiens (human) | IC50 | 3.5800 | 1 | 1 |
| ik 682 | Homo sapiens (human) | IC50 | 2.0500 | 1 | 1 |
| ik 682 | Homo sapiens (human) | Ki | 2.0500 | 3 | 3 |
| bay 12-9566 | Homo sapiens (human) | IC50 | 0.0110 | 1 | 1 |
| bay 12-9566 | Homo sapiens (human) | Ki | 0.0110 | 1 | 1 |
| chlorhexidine | Homo sapiens (human) | IC50 | 7.6300 | 1 | 1 |
| epigallocatechin-3-o-(3''-o-methyl)-gallate | Homo sapiens (human) | IC50 | 8.7000 | 1 | 1 |
| (11c)cgs 25966 | Homo sapiens (human) | IC50 | 0.0110 | 1 | 1 |
| (11c)cgs 25966 | Homo sapiens (human) | Ki | 0.0174 | 5 | 5 |
| bb-78485 | Homo sapiens (human) | IC50 | 0.0175 | 1 | 1 |
| ro 32-3555 | Homo sapiens (human) | IC50 | 0.1540 | 1 | 1 |
| ro 32-3555 | Homo sapiens (human) | Ki | 0.1540 | 1 | 1 |
| ro 28-2653 | Homo sapiens (human) | IC50 | 0.0230 | 1 | 1 |
| abt-770 | Homo sapiens (human) | IC50 | 0.0040 | 3 | 3 |
| sb 3ct compound | Homo sapiens (human) | Ki | 0.0620 | 7 | 8 |
| pd 166793 | Homo sapiens (human) | IC50 | 0.0148 | 4 | 4 |
| pd 166793 | Homo sapiens (human) | Ki | 0.0044 | 1 | 1 |
| sc 78080 | Homo sapiens (human) | IC50 | 0.0001 | 2 | 2 |
| ro 31-9790 | Homo sapiens (human) | IC50 | 0.0074 | 1 | 1 |
| n-((2s)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-l-leucyl-n,3- dimethyl-l-valinamide | Homo sapiens (human) | IC50 | 0.0410 | 1 | 1 |
| 2-[[4-(4-bromophenyl)phenyl]sulfonylamino]-3-methylbutanoic acid | Homo sapiens (human) | IC50 | 0.0000 | 1 | 1 |
| 2-[[4-(4-bromophenyl)phenyl]sulfonylamino]-3-methylbutanoic acid | Homo sapiens (human) | Ki | 2.0000 | 1 | 1 |
| arp-100 | Homo sapiens (human) | IC50 | 0.0120 | 6 | 6 |
| arp-100 | Homo sapiens (human) | Ki | 0.0130 | 1 | 1 |
| kb r8301 | Homo sapiens (human) | IC50 | 0.0003 | 1 | 1 |
| ageladine a | Homo sapiens (human) | IC50 | 1.7000 | 1 | 1 |
| s 3304 | Homo sapiens (human) | IC50 | 0.0108 | 2 | 2 |
| N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide | Homo sapiens (human) | IC50 | 0.0006 | 3 | 3 |
| bms-566394 | Homo sapiens (human) | Ki | 6.6665 | 2 | 2 |
| ks370g | Homo sapiens (human) | IC50 | 0.0082 | 1 | 1 |
| incb3619 | Homo sapiens (human) | IC50 | 0.0370 | 2 | 2 |
| tosedostat | Homo sapiens (human) | IC50 | 0.1900 | 1 | 1 |
| alendronate sodium | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| grassystatin a | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| (4-(n-hydroxyamino)-2r-isobutyl-3s-methylsuccinyl)-l-phenylglycine-n-methylamide | Homo sapiens (human) | IC50 | 0.0013 | 1 | 1 |
| tetracycline | Homo sapiens (human) | IC50 | 220.0000 | 1 | 1 |
| guanosine diphosphate | Homo sapiens (human) | IC50 | 125.2600 | 1 | 5 |
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| marimastat | Homo sapiens (human) | Activity | 0.0008 | 1 | 1 |
| prinomastat | Homo sapiens (human) | Activity | 0.0003 | 1 | 1 |
| rs-130830 | Homo sapiens (human) | Activity | 0.0004 | 1 | 1 |
Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 19, Issue:15, 2009
Inhibition of fucosyltransferase VII by gallic acid and its derivatives.Archives of biochemistry and biophysics, , May-01, Volume: 425, Issue:1, 2004
Dual carbonic anhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acid moieties targeting bone tumors.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 24, Issue:12, 2014
Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.Bioorganic & medicinal chemistry, , Nov-01, Volume: 21, Issue:21, 2013
Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.Bioorganic & medicinal chemistry, , Jun-01, Volume: 22, Issue:11, 2014
Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.Bioorganic & medicinal chemistry letters, , May-01, Volume: 23, Issue:9, 2013
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.ACS medicinal chemistry letters, , Dec-13, Volume: 3, Issue:12, 2012
Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors.Bioorganic & medicinal chemistry, , Jun-15, Volume: 20, Issue:12, 2012
Synthesis of a novel series of L-isoserine derivatives as aminopeptidase N inhibitors.Journal of enzyme inhibition and medicinal chemistry, , Volume: 27, Issue:2, 2012
Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.Bioorganic & medicinal chemistry, , Sep-01, Volume: 19, Issue:17, 2011
Design, synthesis and biological evaluation of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors.Bioorganic & medicinal chemistry, , Oct-15, Volume: 19, Issue:20, 2011
Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N'-substituted-2,6-piperidinedione.Bioorganic & medicinal chemistry, , Aug-15, Volume: 18, Issue:16, 2010
Design, synthesis and primary activity assay of bi- or tri-peptide analogues with the scaffold l-arginine as amino-peptidase N/CD13 inhibitors.Bioorganic & medicinal chemistry, , Jan-15, Volume: 18, Issue:2, 2010
Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part II).Bioorganic & medicinal chemistry, , Apr-15, Volume: 17, Issue:8, 2009
Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part I).Bioorganic & medicinal chemistry, , Apr-15, Volume: 17, Issue:8, 2009
Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13.Bioorganic & medicinal chemistry, , Oct-15, Volume: 17, Issue:20, 2009
Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors.Bioorganic & medicinal chemistry, , Jul-01, Volume: 17, Issue:13, 2009
Novel aminopeptidase N inhibitors derived from 1,3,4-thiadiazole scaffold.Bioorganic & medicinal chemistry, , Jul-15, Volume: 16, Issue:14, 2008
Novel 3-phenylpropane-1,2-diamine derivates as inhibitors of aminopeptidase N (APN).Bioorganic & medicinal chemistry, , Dec-01, Volume: 16, Issue:23, 2008
Design, synthesis, and QSAR studies of novel lysine derives as amino-peptidase N/CD13 inhibitors.Bioorganic & medicinal chemistry, , May-15, Volume: 16, Issue:10, 2008
Novel 3-galloylamido-N'-substituted-2,6-piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors.Bioorganic & medicinal chemistry letters, , May-15, Volume: 17, Issue:10, 2007
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
Discovery of Phenolic Matrix Metalloproteinase Inhibitors by Peptide Microarray for Osteosarcoma Treatment.Journal of natural products, , 10-28, Volume: 85, Issue:10, 2022
Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.Journal of medicinal chemistry, , 01-24, Volume: 62, Issue:2, 2019
Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.Journal of medicinal chemistry, , 08-08, Volume: 62, Issue:15, 2019
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential TreatJournal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.Journal of medicinal chemistry, , May-23, Volume: 45, Issue:11, 2002
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Jan-03, Volume: 45, Issue:1, 2002
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.Bioorganic & medicinal chemistry letters, , Feb-12, Volume: 11, Issue:3, 2001
alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.Bioorganic & medicinal chemistry letters, , Oct-22, Volume: 11, Issue:20, 2001
Selective, orally active MMP inhibitors with an aryl backbone.Bioorganic & medicinal chemistry letters, , Sep-17, Volume: 11, Issue:18, 2001
Synthesis and activity of selective MMP inhibitors with an aryl backbone.Bioorganic & medicinal chemistry letters, , Dec-18, Volume: 10, Issue:24, 2000
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.Bioorganic & medicinal chemistry letters, , Oct-04, Volume: 9, Issue:19, 1999
Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.Bioorganic & medicinal chemistry letters, , Jun-21, Volume: 9, Issue:12, 1999
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.Bioorganic & medicinal chemistry letters, , Nov-17, Volume: 8, Issue:22, 1998
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.Journal of medicinal chemistry, , Apr-09, Volume: 41, Issue:8, 1998
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.Journal of medicinal chemistry, , Jul-31, Volume: 46, Issue:16, 2003
Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.Journal of medicinal chemistry, , Oct-11, Volume: 44, Issue:21, 2001
Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis.Journal of medicinal chemistry, , 06-23, Volume: 65, Issue:12, 2022
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
[no title available]Journal of medicinal chemistry, , 12-10, Volume: 63, Issue:23, 2020
Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.Bioorganic & medicinal chemistry letters, , May-01, Volume: 26, Issue:9, 2016
Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.European journal of medicinal chemistry, , Volume: 62, 2013
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.Bioorganic & medicinal chemistry, , Sep-15, Volume: 16, Issue:18, 2008
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.The Journal of biological chemistry, , Sep-21, Volume: 282, Issue:38, 2007
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.Bioorganic & medicinal chemistry, , Jul-15, Volume: 15, Issue:14, 2007
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.Journal of medicinal chemistry, , Jan-26, Volume: 49, Issue:2, 2006
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.Bioorganic & medicinal chemistry letters, , Jan-05, Volume: 14, Issue:1, 2004
Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives.Bioorganic & medicinal chemistry letters, , May-19, Volume: 13, Issue:10, 2003
MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 13, Issue:17, 2003
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.Bioorganic & medicinal chemistry letters, , Feb-26, Volume: 11, Issue:4, 2001
Matrix metalloproteinase inhibitors: a structure-activity study.Journal of medicinal chemistry, , Jan-15, Volume: 41, Issue:2, 1998
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.Journal of medicinal chemistry, , Apr-09, Volume: 41, Issue:8, 1998
Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.Bioorganic & medicinal chemistry, , 05-15, Volume: 27, Issue:10, 2019
Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP).Bioorganic & medicinal chemistry, , 01-01, Volume: 27, Issue:1, 2019
Lung cancer and matrix metalloproteinases inhibitors of polyphenols from Selaginella tamariscina with suppression activity of migration.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 28, Issue:14, 2018
Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.Journal of medicinal chemistry, , Aug-01, Volume: 40, Issue:16, 1997
[no title available]European journal of medicinal chemistry, , Nov-01, Volume: 181, 2019
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 15, Issue:5, 2005
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.Journal of medicinal chemistry, , Jan-15, Volume: 47, Issue:2, 2004
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.Bioorganic & medicinal chemistry letters, , Oct-07, Volume: 12, Issue:19, 2002
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Jan-03, Volume: 45, Issue:1, 2002
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.Bioorganic & medicinal chemistry letters, , Feb-12, Volume: 11, Issue:3, 2001
Selective, orally active MMP inhibitors with an aryl backbone.Bioorganic & medicinal chemistry letters, , Sep-17, Volume: 11, Issue:18, 2001
Synthesis and activity of selective MMP inhibitors with an aryl backbone.Bioorganic & medicinal chemistry letters, , Dec-18, Volume: 10, Issue:24, 2000
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Nov-04, Volume: 42, Issue:22, 1999
Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.Journal of medicinal chemistry, , 01-26, Volume: 60, Issue:2, 2017
Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.Bioorganic & medicinal chemistry, , 12-01, Volume: 24, Issue:23, 2016
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.Bioorganic & medicinal chemistry, , Oct-01, Volume: 22, Issue:19, 2014
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.Journal of medicinal chemistry, , Nov-13, Volume: 57, Issue:21, 2014
Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.Journal of medicinal chemistry, , Jun-11, Volume: 52, Issue:11, 2009
Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.Journal of medicinal chemistry, , Oct-20, Volume: 48, Issue:21, 2005
Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 15, Issue:4, 2005
Selective, orally active MMP inhibitors with an aryl backbone.Bioorganic & medicinal chemistry letters, , Sep-17, Volume: 11, Issue:18, 2001
Synthesis and activity of selective MMP inhibitors with an aryl backbone.Bioorganic & medicinal chemistry letters, , Dec-18, Volume: 10, Issue:24, 2000
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Current perspective of TACE inhibitors: a review.Bioorganic & medicinal chemistry, , Jan-15, Volume: 17, Issue:2, 2009
Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.Bioorganic & medicinal chemistry, , Sep-15, Volume: 15, Issue:18, 2007
Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheuThe Journal of pharmacology and experimental therapeutics, , Volume: 309, Issue:1, 2004
[no title available]RSC medicinal chemistry, , Oct-20, Volume: 12, Issue:10, 2021
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.Bioorganic & medicinal chemistry letters, , Jan-03, Volume: 15, Issue:1, 2005
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.Journal of medicinal chemistry, , Jul-31, Volume: 46, Issue:16, 2003
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.Bioorganic & medicinal chemistry letters, , Feb-26, Volume: 11, Issue:4, 2001
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.Bioorganic & medicinal chemistry letters, , Nov-17, Volume: 8, Issue:22, 1998
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.Journal of medicinal chemistry, , Apr-09, Volume: 41, Issue:8, 1998
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).Bioorganic & medicinal chemistry letters, , May-15, Volume: 17, Issue:10, 2007
Identification of potent and selective TACE inhibitors via the S1 pocket.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 17, Issue:1, 2007
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.Journal of medicinal chemistry, , Nov-07, Volume: 45, Issue:23, 2002
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Jan-03, Volume: 45, Issue:1, 2002
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.Bioorganic & medicinal chemistry, , Jul-01, Volume: 23, Issue:13, 2015
Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.Journal of medicinal chemistry, , Sep-12, Volume: 56, Issue:17, 2013
A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.Journal of medicinal chemistry, , May-24, Volume: 55, Issue:10, 2012
Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.Journal of medicinal chemistry, , Aug-01, Volume: 40, Issue:16, 1997
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.Bioorganic & medicinal chemistry letters, , Jun-18, Volume: 11, Issue:12, 2001
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and Challenges.Journal of medicinal chemistry, , 10-08, Volume: 63, Issue:19, 2020
Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing.Journal of medicinal chemistry, , 10-11, Volume: 61, Issue:19, 2018
Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.ACS medicinal chemistry letters, , Jun-14, Volume: 3, Issue:6, 2012
Sulfonate-containing thiiranes as selective gelatinase inhibitors.ACS medicinal chemistry letters, , Feb-10, Volume: 2, Issue:2, 2011
Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases.Chemical biology & drug design, , Volume: 74, Issue:6, 2009
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
Sulphonamides: Deserving class as MMP inhibitors?European journal of medicinal chemistry, , Volume: 60, 2013
Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates.Journal of medicinal chemistry, , Feb-09, Volume: 49, Issue:3, 2006
Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.Journal of medicinal chemistry, , Jan-27, Volume: 43, Issue:2, 2000
MMP-13 selective α-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.Bioorganic & medicinal chemistry letters, , May-15, Volume: 21, Issue:10, 2011
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.Journal of medicinal chemistry, , Sep-23, Volume: 53, Issue:18, 2010
Sulphonamides: Deserving class as MMP inhibitors?European journal of medicinal chemistry, , Volume: 60, 2013
Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.Bioorganic & medicinal chemistry letters, , Oct-07, Volume: 12, Issue:19, 2002
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.Journal of medicinal chemistry, , 08-25, Volume: 65, Issue:16, 2022
Sulphonamides: Deserving class as MMP inhibitors?European journal of medicinal chemistry, , Volume: 60, 2013
Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.Journal of medicinal chemistry, , Mar-25, Volume: 53, Issue:6, 2010
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.Journal of medicinal chemistry, , Aug-13, Volume: 52, Issue:15, 2009
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 15, Issue:5, 2005
Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.Journal of medicinal chemistry, , May-20, Volume: 42, Issue:10, 1999
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.Journal of medicinal chemistry, , Feb-12, Volume: 41, Issue:4, 1998
Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.European journal of medicinal chemistry, , Jan-27, Volume: 108, 2016
Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.Journal of medicinal chemistry, , Oct-22, Volume: 52, Issue:20, 2009
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 15, Issue:5, 2005
Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 18, Issue:5, 2008
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.Bioorganic & medicinal chemistry, , Oct-01, Volume: 16, Issue:19, 2008
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.Journal of medicinal chemistry, , Feb-22, Volume: 50, Issue:4, 2007
Enables
This protein enables 7 target(s):
| Target | Category | Definition |
|---|
| fibronectin binding | molecular function | Binding to a fibronectin, a group of related adhesive glycoproteins of high molecular weight found on the surface of animal cells, connective tissue matrices, and in extracellular fluids. [GOC:hjd] |
| endopeptidase activity | molecular function | Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain. [http://merops.sanger.ac.uk/about/glossary.htm#ENDOPEPTIDASE] |
| metalloendopeptidase activity | molecular function | Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions. [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE, https://www.ebi.ac.uk/merops/about/glossary.shtml#ENDOPEPTIDASE] |
| serine-type endopeptidase activity | molecular function | Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine). [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| metallopeptidase activity | molecular function | Catalysis of the hydrolysis of peptide bonds by a mechanism in which water acts as a nucleophile, one or two metal ions hold the water molecule in place, and charged amino acid side chains are ligands for the metal ions. [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE] |
| zinc ion binding | molecular function | Binding to a zinc ion (Zn). [GOC:ai] |
Located In
This protein is located in 7 target(s):
| Target | Category | Definition |
|---|
| extracellular region | cellular component | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. [GOC:go_curators] |
| extracellular space | cellular component | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. [ISBN:0198547684] |
| nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
| mitochondrion | cellular component | A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration. [GOC:giardia, ISBN:0198506732] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| sarcomere | cellular component | The repeating unit of a myofibril in a muscle cell, composed of an array of overlapping thick and thin filaments between two adjacent Z discs. [ISBN:0815316194] |
| collagen-containing extracellular matrix | cellular component | An extracellular matrix consisting mainly of proteins (especially collagen) and glycosaminoglycans (mostly as proteoglycans) that provides not only essential physical scaffolding for the cellular constituents but can also initiate crucial biochemical and biomechanical cues required for tissue morphogenesis, differentiation and homeostasis. The components are secreted by cells in the vicinity and form a sheet underlying or overlying cells such as endothelial and epithelial cells. [GOC:BHF, GOC:rph, PMID:21123617] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| extracellular space | cellular component | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. [ISBN:0198547684] |
Involved In
This protein is involved in 45 target(s):
| Target | Category | Definition |
|---|
| angiogenesis | biological process | Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels. [ISBN:0878932453] |
| ovarian follicle development | biological process | The process whose specific outcome is the progression of the ovarian follicle over time, from its formation to the mature structure. [https://www.ncbi.nlm.nih.gov/books/NBK279054/] |
| ovulation from ovarian follicle | biological process | The process leading to the rupture of the follicle, releasing the centrally located oocyte into the oviduct. An example of this is found in Mus musculus. [GOC:mtg_sensu, https://www.ncbi.nlm.nih.gov/books/NBK279054/] |
| luteinization | biological process | The set of processes resulting in differentiation of theca and granulosa cells into luteal cells and in the formation of a corpus luteum after ovulation. [https://www.ncbi.nlm.nih.gov/books/NBK279054/] |
| blood vessel maturation | biological process | A developmental process, independent of morphogenetic (shape) change, that is required for a blood vessel to attain its fully functional state. [GOC:dph] |
| intramembranous ossification | biological process | Direct ossification that occurs within mesenchyme or an accumulation of relatively unspecialized cells. [ISBN:0878932437] |
| proteolysis | biological process | The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds. [GOC:bf, GOC:mah] |
| negative regulation of cell adhesion | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell adhesion. [GOC:go_curators] |
| heart development | biological process | The process whose specific outcome is the progression of the heart over time, from its formation to the mature structure. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood. [GOC:jid, UBERON:0000948] |
| embryo implantation | biological process | Attachment of the blastocyst to the uterine lining. [GOC:isa_complete, http://www.medterms.com] |
| parturition | biological process | The reproductive process in which the parent is separated from its offspring either by giving birth to live young or by laying eggs. [ISBN:0198506732] |
| response to xenobiotic stimulus | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organim exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. [GOC:jl, GOC:krc] |
| response to mechanical stimulus | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mechanical stimulus. [GOC:hb] |
| peripheral nervous system axon regeneration | biological process | The regrowth of axons outside the central nervous system (outside the brain and spinal cord) following an axonal injury. [GOC:ef] |
| response to activity | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an activity stimulus. [GOC:mtg_muscle] |
| protein metabolic process | biological process | The chemical reactions and pathways involving a protein. Includes protein modification. [GOC:ma] |
| extracellular matrix disassembly | biological process | A process that results in the breakdown of the extracellular matrix. [GOC:jid] |
| protein catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds. [GOC:mah] |
| positive regulation of cell migration | biological process | Any process that activates or increases the frequency, rate or extent of cell migration. [GOC:go_curators] |
| collagen catabolic process | biological process | The proteolytic chemical reactions and pathways resulting in the breakdown of collagen in the extracellular matrix, usually carried out by proteases secreted by nearby cells. [GOC:mah, ISBN:0815316194] |
| response to retinoic acid | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a retinoic acid stimulus. [GOC:sl] |
| cellular response to reactive oxygen species | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a reactive oxygen species stimulus. Reactive oxygen species include singlet oxygen, superoxide, and oxygen free radicals. [GOC:mah] |
| response to nicotine | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nicotine stimulus. [GOC:bf, GOC:ef, ISBN:0198506732, ISBN:0582227089] |
| endodermal cell differentiation | biological process | The process in which a relatively unspecialized cell acquires the specialized features of an endoderm cell, a cell of the inner of the three germ layers of the embryo. [CL:0000223, GOC:yaf, PMID:17624332] |
| response to hydrogen peroxide | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen peroxide (H2O2) stimulus. [GOC:jl] |
| response to estrogen | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by an estrogen, C18 steroid hormones that can stimulate the development of female sexual characteristics. [GOC:jl, ISBN:0198506732] |
| negative regulation of vasoconstriction | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of vasoconstriction. [GOC:go_curators] |
| ephrin receptor signaling pathway | biological process | The series of molecular signals initiated by ephrin binding to its receptor, and ending with the regulation of a downstream cellular process, e.g. transcription. [GOC:ceb] |
| macrophage chemotaxis | biological process | The movement of a macrophage in response to an external stimulus. [GOC:jid] |
| response to electrical stimulus | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electrical stimulus. [GOC:ai] |
| response to hyperoxia | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating increased oxygen tension. [GOC:kmv] |
| face morphogenesis | biological process | The process in which the anatomical structures of the face are generated and organized. The face is the ventral division of the head. [GOC:dph] |
| bone trabecula formation | biological process | The process of creating a trabecula in the bone. A trabecula is a tissue element in the form of a small beam, strut or rod. [GOC:dph] |
| prostate gland epithelium morphogenesis | biological process | The process in which the anatomical structures of epithelia of the prostate gland are generated and organized. An epithelium consists of closely packed cells arranged in one or more layers, that covers the outer surfaces of the body or lines any internal cavity or tube. [GOC:dph] |
| cellular response to amino acid stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amino acid stimulus. An amino acid is a carboxylic acids containing one or more amino groups. [GOC:mah] |
| cellular response to interleukin-1 | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-1 stimulus. [GOC:mah] |
| cellular response to estradiol stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by estradiol, a C18 steroid hormone hydroxylated at C3 and C17 that acts as a potent estrogen. [GOC:mah] |
| cellular response to UV-A | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a UV-A radiation stimulus. UV-A radiation (UV-A light) spans the wavelengths 315 to 400 nm. [GOC:mah] |
| cellular response to fluid shear stress | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fluid shear stress stimulus. Fluid shear stress is the force acting on an object in a system where the fluid is moving across a solid surface. [GOC:mah] |
| positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | biological process | Any process that activates or increases the frequency, rate or extent of oxidative stress-induced neuron intrinsic apoptotic signaling pathway. [GO_REF:0000058, GOC:bf, GOC:PARL, GOC:TermGenie] |
| response to amyloid-beta | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a amyloid-beta stimulus. [GO_REF:0000071, GOC:TermGenie, PMID:23555824] |
| positive regulation of vascular associated smooth muscle cell proliferation | biological process | Any process that activates or increases the frequency, rate or extent of vascular smooth muscle cell proliferation. [GO_REF:0000058, GOC:TermGenie, PMID:23246467] |
| extracellular matrix organization | biological process | A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an extracellular matrix. [GOC:mah] |
| response to hypoxia | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. [GOC:hjd] |
| tissue remodeling | biological process | The reorganization or renovation of existing tissues. This process can either change the characteristics of a tissue such as in blood vessel remodeling, or result in the dynamic equilibrium of a tissue such as in bone remodeling. [GOC:ebc] |